Skip to main content
Fig. 2 | Journal of Neuroinflammation

Fig. 2

From: Inhibition of discoidin domain receptor (DDR)-1 with nilotinib alters CSF miRNAs and is associated with reduced inflammation and vascular fibrosis in Alzheimer’s disease

Fig. 2

DDR1 is longitudinally inhibited in the CSF of AD patients treated with nilotinib. ELISA measurement of pan-tyrosine phosphorylated DDR1 (pDDR1) shows the slope (m) of log10 linear regression of mean difference values in the CSF of A) AD patients from baseline-end of treatment, indicating (rising slopes) an increase in active pDDR1 level over time. Nilotinib treatment B) results in slower slope (m) of log10 linear regression of mean difference values between baseline and end of treatment in AD patients treated with nilotinib, indicating reduction of pDDR1 (active). N = 12 placebo and n = 12 in nilotinib. C) measurement of plasma Aβ42 and pTau217 using Biofluid Biomarker Assay via SQUID IMR (Immuno Magnetic Reagents) Platform (MagQu Co., Ltd). N = 12 placebo and N = 10 nilotinib. Graphed as mean ± standard error of the mean. The changes in the ratio of Aβ42/pTau (217) across each group were compared using a one‐tailed unpaired t‐test with Welch's corrections. Asterisks denote actual P‐value significances (*P < 0.05) between groups and are noted in the figure. Statistical analysis was performed using GraphPad Prism, version 9.1.2 (GraphPad Software Inc.)

Back to article page

Journal of Neuroinflammation

ISSN: 1742-2094